Robin Joan Steele - 11 Jun 2026 Form 4 Insider Report for Dare Bioscience, Inc. (DARE)

Reporting relationship: Director
Issuer ticker: DARE
Reported as of: 11 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jun 2026, 16:58:47 UTC
Prior SEC filing: 10 Jul 2025
Next SEC filing: 02 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Sabrina Martucci Johnson, Attorney-in-fact

Key filing fact

Robin Joan Steele filed Form 4 for Dare Bioscience, Inc. (DARE) on 11 Jun 2026.

Key facts

This page summarizes Robin Joan Steele's Form 4 filing for Dare Bioscience, Inc. (DARE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Jun 2026, 16:58.

Change

Previous filing in this sequence was filed on 10 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001301008 Primary reporting owner

Steele Robin Joan

Relationship: Director
Address: 3655 NOBEL DRIVE, SUITE 260, SAN DIEGO
Signature: /s/ Sabrina Martucci Johnson, Attorney-in-fact
Signature date: 11 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DARE transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +10,000
Change %
Price: $0.000000^*
Shares after: 10,000
Date: 11 Jun 2026
Ownership: Direct
Underlying class: Common stock
Underlying amount: 10,000
Exercise price: $2.03
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer.